TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB
P160906J
Phase 2 small_molecule active
Quick answer
TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB for Patients displaying a non-classified, severe and resistant inflammatory disease is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Patients displaying a non-classified, severe and resistant inflammatory disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active